Study examines safety and effectiveness of infliximab biosimilar in patients with inflammatory bowel

December 06, 2017

Biosimilars are biologic agents that highly similar to original biomedical medications (oringinators), but are much cheaper. A new study in Alimentary Pharmacology & Therapeutics found no differences in drug levels and disease activity between infliximab originator and an infliximab biosimilar in patients with inflammatory bowel disease, indicating that this biosimilar is indeed safe and effective.

After switching to an infliximab biosimilar, 26% of patients discontinued therapy within 12 months. This high rate of discontinuation was likely due to elective withdrawal or subjective disease worsening.

"Switching to biosimilars and performing therapeutic drug monitoring as part of routine care can optimize infliximab therapy of inflammatory bowel disease efficiently and make it more cost-effective," said senior author Dr. Luc Derijks, of the Máxima Medical Center, in The Netherlands.
-end-


Wiley

Related Inflammatory Bowel Disease Articles from Brightsurf:

People with inflammatory bowel disease still die earlier despite increase in life
A study comparing life expectancy of people with inflammatory bowel disease (IBD) and without found that, while life expectancy increased for both groups, people with IBD generally died sooner.

Cell therapy designed to treat inflammatory bowel disease
The UPV/EHU's NanoBioCel research group has for many years been developing systems enabling cells to be used as drugs.

Team develops wearable sensor to help people with inflammatory bowel disease
University of Texas at Dallas researchers have designed a wearable device that monitors sweat for biomarkers that could signal flare-ups of inflammatory bowel disease (IBD).

Antibiotics associated with increased risk of inflammatory bowel disease
Antibiotics use, particularly antibiotics with greater spectrum of microbial coverage, may be associated with an increased risk of new-onset inflammatory bowel disease (IBD) and its subtypes ulcerative colitis and Crohn's disease.

Yes, inflammatory bowel disease and celiac disease are linked
A systematic review and meta-analysis that has determined there is a nine-fold increased risk of having IBD for patients with a previous diagnosis of celiac disease.

The effects of inflammatory bowel disease on pregnancy
Inflammatory bowel disease (IBD) -- including Crohn's disease and ulcerative colitis -- often affects women of childbearing age.

5 major advances in inflammatory bowel disease (IBD) treatment
Summary of five impactful studies to be presented at the Crohn's & Colitis Congress, a partnership of the Crohn's & Colitis Foundation and the American Gastroenterological Association (AGA).

Researchers identify a possible cause and treatment for inflammatory bowel disease
In a study published online in PNAS on Jan. 20, 2020, Prof.

Does inflammatory bowel disease carry certain risks during pregnancy?
Pregnant women with inflammatory bowel disease (IBD) are more likely to undergo delivery by Caesarean section and face certain risks during pregnancy, according to an analysis published in Alimentary Pharmacology & Therapeutics.

Inhibiting a protease could improve the treatment of inflammatory bowel disease
Scientists at the CNIC and CSIC have identified a function of a protease that could be the future target of drugs to treat inflammatory bowel disease.

Read More: Inflammatory Bowel Disease News and Inflammatory Bowel Disease Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.